Inicio>>Signaling Pathways>> Membrane Transporter/Ion Channel>> iGluR>>Sepimostat dimethanesulfonate

Sepimostat dimethanesulfonate

Catalog No.GC61570

El dimetanosulfonato de sepimostato (FUT-187) exhibe actividad neuroprotectora a través del antagonismo del receptor de N-metil-D-aspartato NR2B en el sitio de uniÓn de Ifenprodil de la subunidad NR2B.

Products are for research use only. Not for human use. We do not sell to patients.

Sepimostat dimethanesulfonate Chemical Structure

Cas No.: 103926-82-5

Tamaño Precio Disponibilidad Cantidad
5 mg
278,00 $
Disponible
10 mg
464,00 $
Disponible
25 mg
881,00 $
Disponible
50 mg
1.437,00 $
Disponible
100 mg
2.178,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Sepimostat dimethanesulfonate (FUT-187) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat dimethanesulfonate inhibits the Ifenprodil binding with a Ki value of 27.7 µM[1].

Sepimostat (1 to 100 nmol/eye, intravitreal injection) exhibits significant neuroprotective effect[1]. Animal Model: Male Sprague Dawley rats weighing 150-300 g[1].

[1]. Masahiro Fuwa, et al. Nafamostat and Sepimostat Identified as Novel Neuroprotective Agents via NR2B N-methyl-D-aspartate Receptor Antagonism Using a Rat Retinal Excitotoxicity Model. Sci Rep. 2019 Dec 31;9(1):20409.

Reseñas

Review for Sepimostat dimethanesulfonate

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sepimostat dimethanesulfonate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.